These studies showed that the antitumor effects were associated with the infiltration of CD8+ tumor-infiltrating lymphocytes, and proposed that PAP (114–128) is a highly relevant peptide on which to base vaccines for the treatment of prostate cancer. The gene discussed is CD8A; the disease is prostate cancer.